HEPA vs. LGVN, MTEM, ADIL, VIRI, CYCN, AKTX, BFRI, GRTX, TFFP, and AEZS
Should you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Longeveron (LGVN), Molecular Templates (MTEM), Adial Pharmaceuticals (ADIL), Virios Therapeutics (VIRI), Cyclerion Therapeutics (CYCN), Akari Therapeutics (AKTX), Biofrontera (BFRI), Galera Therapeutics (GRTX), TFF Pharmaceuticals (TFFP), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical preparations" industry.
Hepion Pharmaceuticals (NASDAQ:HEPA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Hepion Pharmaceuticals received 15 more outperform votes than Longeveron when rated by MarketBeat users. However, 85.71% of users gave Longeveron an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote.
Hepion Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
In the previous week, Hepion Pharmaceuticals had 9 more articles in the media than Longeveron. MarketBeat recorded 11 mentions for Hepion Pharmaceuticals and 2 mentions for Longeveron. Longeveron's average media sentiment score of 0.32 beat Hepion Pharmaceuticals' score of -0.02 indicating that Longeveron is being referred to more favorably in the news media.
Longeveron has a consensus target price of $60.00, indicating a potential upside of 3,429.41%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Hepion Pharmaceuticals.
Longeveron has higher revenue and earnings than Hepion Pharmaceuticals. Longeveron is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 2.0% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Hepion Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -3,020.17%. Longeveron's return on equity of -209.14% beat Hepion Pharmaceuticals' return on equity.
Summary
Longeveron beats Hepion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Hepion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hepion Pharmaceuticals Competitors List
Related Companies and Tools
